MedTrace Logo

Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation

NCT03796507 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2021-04-09

No results posted yet for this study

Summary

The purpose of this study is to investigate the feasibility of a possible treatment regimen that could be used to delay tumor progression in patients with glioblastoma. The study is being conducted in patients who qualify for inpatient rehabilitation, as this population is particularly vulnerable to delays in initiation of chemoradiation and further tumor growth in the period between surgical resection and the start of treatment.

Conditions

  • Glioma of Brain

Interventions

DRUG

Temozolomide

oral temozolomide at 75 mg per square meter of body surface area daily for 21 days

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • University of Rochester

    lead OTHER

Principal Investigators

  • Kevin A Walter, MD · University of Rochester Medical Center, Dept. of Neurosurgery

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2021-12-15
Completion
2021-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03796507 on ClinicalTrials.gov